64 citations,
September 2006 in “International journal of epidemiology” Cancer development is like natural selection, involving mutated cells and environmental factors.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
October 2014 in “Aktuelle Dermatologie” Older men with scalp wounds had long-term healing problems after using imiquimod or diclofenac for skin cancer prevention.
25 citations,
February 2009 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
45 citations,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
16 citations,
October 2023 in “Molecular cancer” New treatments like nanotechnology show promise in improving skin cancer therapy.
9 citations,
February 2022 in “Biomolecules” Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
January 2016 in “Hair transplant forum international” Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
15 citations,
August 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
2 citations,
September 2010 in “Journal of the Dermatology Nurses’ Association” Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.
1 citations,
July 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
June 2011 in “Expert Review of Dermatology” Researchers discovered potential origins and new treatments for skin cancer, including biomarkers for melanoma and therapies that reduce tumor growth.
45 citations,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
165 citations,
November 2003 in “Toxicology and applied pharmacology” Blocking COX, especially COX-2, in the skin can reduce inflammation and pain and may help prevent skin cancer.
51 citations,
September 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
3 citations,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
44 citations,
March 2018 in “British Journal of Dermatology” Botulinum toxin has potential for treating various skin conditions and improving wound healing.
29 citations,
December 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
73 citations,
September 2016 in “Journal of Translational Medicine” Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
3 citations,
April 2017 in “Sexual medicine reviews” The document concludes that better research methods are needed in men's sexual health to provide stronger evidence and improve patient care.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
38 citations,
January 2001 in “Neuroepidemiology” The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
223 citations,
March 2011 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
139 citations,
November 2015 in “Journal of Advanced Research” Vitamin D is important for skin health and may affect conditions like psoriasis and hair loss, but more research is needed to understand its role fully.
28 citations,
September 2013 in “Expert Opinion on Therapeutic Patents” New resveratrol-related compounds show promise for treating various health issues but need more research for clinical use.